Recombinant human activated protein C as a therapy for pre-eclampsia
INTRODUCTION: Pre-eclampsia remains one of the most common causes of maternal mortality in the developed world, and we still have no known effective prophylaxis and proven modifiers. The recent successful clinical trial of recombinant human activated protein C (rhAPC) in the management of SIRS (s...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2011
|
| Online Access: | http://hdl.handle.net/2429/32051 |